Heart Failure

Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

A multicenter study found guideline-based grading underestimates tricuspid regurgitation severity and risk in ATTR-CM.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Experts discuss why patients with HFmrEF/HFpEF still receive less urgent, less standardized care than those with reduced ejection fraction.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

Boston heart failure specialists discussed diagnostic gaps, cost barriers to newer therapies, and scalable care models for HFpEF and HFmrEF.

A new analysis finds up to a 98.8% probability that liberal transfusion lowers 30-day death or myocardial infarction risk vs restrictive care.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

An analysis found no significant differences in care escalation, readmission, mortality, or guideline-directed therapy use between home-based and inpatient care.

In this study, 13% of patients who stopped heart failure medications after successful AF ablation had HF deterioration vs none who continued treatment.

A Brown University–led review synthesizes GDMT, comorbidity management, and emerging therapies into a hospital-based framework for HFpEF.

A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.

A study found significant drops in mean platelet volume and rises in platelet count after 6 months of SGLT2 inhibitor therapy, independent of diuretic use.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

Researchers found persistent and substantial delays between heart failure diagnosis and ATTR-CM identification.

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.